On December 27th, 2023, CCADD held the year-end workshop at Front1, a startup hub at the heart of Seoul, where PMACH is based. This year, Prof. Howard Lee and the members of CCADD were joined by PMATCH and Dr. Siun Kim. The workshop went on in a dynamic atmosphere, welcoming both Prof. Howard’s part-time student and the interns for the upcoming internship program.

After a brief ice-breaking time, the main session started with a recap of the accomplishments of 2023, reflecting on the overall trajectory. Prof. Howard commended CCADD’s continuous growth in both research and publications. As preparation for 2024, the following session outlined a roadmap, encompassing detailed research ideas and plans for conference to attend in 2024.

The spotlight then turned to CCADD interns. Three passionate interns—Tang Chao, Seorin Choi, and Yunha Noh—who will join the 2024 winter internship program introduced themselves through "Who am I" presentations. Following this, Yujin expressed her aspirations for the path ahead as a new CCADD graduate research student. The workshop proceeded with a lecture on the challenges faced by postdoctoral researchers and strategies for maintaining a healthy mindset among graduate students.

Dr. Siun Kim took a special session to share insights into his post-doctoral journey following graduation. Delivering a lecture on the trending topic of "LLMs in medicine and drug development", he provided valuable perspectives and briefly introduced his ongoing research projects. He candidly shared reflections on the first-year post doc., emphasizing the professional commitment required in the field of research.

Finally, PMATCH summarized their achievements in 2023 and anticipated the upcoming year's developments. With the successful launch of the 'BATTERY' app and a triumphant debut at CES^® 2023, PMATCH envisions a promising future with new team members. Yoomin Jeon, the Chief Technology Officer of PMATCH, expressed her commitment to meeting user’s needs as a must-have app.

The workshop concluded with a keynote address by Prof. Howard. Introducing new trends in 2024, he emphasized the significance of adjusting our research focus and domain knowledge to take another leap forward. Prof. Howard’s central message highlighted 2024 as a pivotal year for CCADD's rebound and PMATCH's inaugural year of growth. 

Yoona Choi and Jung-Hyun Won attended the 65th Annual Meeting & Exposition of the American Society of Hematology (ASH), which took place from December 9 to 12, 2023, in San Diego, USA. Annually, the ASH conference brings together healthcare professionals, researchers, clinicians, and academics from around the globe to explore advancements in hematology. This prestigious event not only focuses on the study, diagnosis, treatment, and prevention of blood disorders but also features a variety of social events and opportunities for collaboration and the sharing of insights among experts in the field. Official photos from ASH are available here.

At the 'Outcomes Research—Lymphoid Malignancies: Poster II' session, Yoona Choi, serving as the first author and representing the entire research team, presented a study titled 'Evaluating the Effectiveness and Safety of Prephase Steroid Treatment before Remission Induction Chemotherapy in Pediatric Acute Lymphoblastic Leukemia: A Common Data Model-Based Real-World Data Approach.' This study investigated steroid pretreatment in pediatric acute lymphoblastic leukemia (ALL) patients undergoing remission induction chemotherapy (RIC), with the aim of reducing complications such as tumor lysis syndrome (TLS). Analyzing data from Seoul National University Hospital and Catholic University Seoul St. Mary’s Hospital, the study compared patients who received steroid pretreatment at least seven days before RIC with those who did not. The findings indicated a significant reduction in TLS incidence in the pretreated group. While overall survival rates were higher in this group, the difference was not statistically significant. These results provide important real-world evidence for the effectiveness of steroid pretreatment in reducing TLS risk in pediatric ALL patients.

This study was part of a larger project, funded by a grant from the Ministry of Health and Welfare, aiming to develop a disease registry database for pediatric ALL using real-world data in the clinical data warehouse (CDW) of Seoul National University Hospital and Catholic University Seoul St. Mary’s Hospital, thereby generating real-world evidence for pediatric ALL. 

Prof. Howard Lee shared his past experiences and future perspectives on the 14C-based microtracing and macrodosing studies in humans in South Korea as an invited speaker to the 9th East Asia Accelerator Mass Spectrometry Symposium (EAAMS-9), held at KIST, Seoul, South Korea, on November 22-24, 2023. 

Prof. Lee has introduced the concept and utilizes of the 14C-based microtracing and macrodosing study for new drug development since 2024. As of today, Prof. Lee has completed a total of six microtracing/microdosing studies with one being the IND-opening study for the US FDA. In his talk, Prof. Lee shared his experiences in starting a 14C-labelled human study using the microdosing technology in Korea. Additionally, Prof. Lee gave hist perspective as to how this technology can be further utilized to increase the efficiency of clinical drug development.

Money Today Broadcasting or MTN interviews Prof. Howard Lee, where he explained why it is indispensable to have a government-wide control tower for new drug development. Prof. Lee stressed the importance of a control tower, preferably set up as an independent, standing government-wide institute that has discretional power over its budget and Human Resources management to maximize its efficiency, which can lead to increased output of new drug development activities in South Korea. His interview can be watched at the following YouTube clip. Additionally, this news article summarizes what Prof. Lee talked in his interview. 

Prof. Lee and David Seung U Lee met with Prof. M. Madan Babu, PhD, FRS, FMedSci, from St. Jude Children's Research Hospital, Memphis, TN, USA, July 17, 2023 in the Grand Hyatt Incheon. Prof. Babu is currently the Endowed Chair in Biomedical Data Science and Director of the Center of Excellence for Data Driven Discovery, St. Jude Children's Research Hospital. He will soon serve as a Senior Vice President and Chief Data Scientist at St. Jude Children's Research Hospital. Prof. Babu is an acclaimed researcher and scientist in various fields including GPCR signaling, regulation and pharmacology, gene , gene regulation, computational biology, structural bioinformatics, and drug discovery. He published many research articles in high-impact journals such as Nature, Science, and Cell. He is also Chief Editor for Molecular Systems Biology journal. 

It has turned out that Prof. Babu had followed the work from CCADD and is interested to know more about what is currently happening in those research areas. In this regard, the main purpose of Prof. Babu's visit this time was to establish professional relationships and set up international scientific bridges with St. Jude to enrich biomedical data science collaborations. Prof. Lee and David detailed the big data science and AI in drug development and optimal usage projects by CCADD, in which Prof. Babu showed great interest. Prof. Babu asked Prof. Lee for additional information and s for those research projects, which David will soon follow up. 

Out of a 3-hour lunch meeting with Prof. Babu, many collaboration opportunities and projects were discussed and proposed, one of which was an exchange program between the two institutions. Co-publication was also talked about, and Prof. Babu asked if CCADD could write a perspective paper regarding drug repurposing using AI for the Molecular Systems Biology journal. Prof. Lee and David hope to see more details soon and will keep CCADD informed. 

Yesol Hong won the Excellent Research Award at the 30th Annual Conference of the Korean Society for Clinical Pharmacology & Therapeutics (KSCPT), December 1-3, 2022, held at Bexco, Busan, South Korea. The title of YeSol's presentation was "One-year follow-up of patients with COVID-19: Analysis of new-onset disease after COVID-19 diagnosis using Real-World Data". She discussed the results of an analysis of the occurrence of disease in patients with COVID-19 over a year using two different real-world data sets. One of her analysis results was a nation-wide study, which was significant in that it included the largest number of study subjects among the studies analyzing the post-COVID-19-condition in Korea. Jung Hyun Won equally contributed to this study with Professor Howard Lee serving as the principal investigator.

Additionally, Siun Kim, Yoona Choi, David Seung U Lee also presented their research through poster exhibition at the conference. 

Full presentations can be watched at the following YouTube links: 

YeSol had the honor to deliver oral presentation and won the Excellent Research Award at 2022 fall conference hosted by the Korean Society of Medical Informatics(KOSMI). YeSol has presented her work entitled "Effectiveness and safety of sodium-glucose cotransporter-2 inhibitors(SGLT2i) added to mono, dual or triple treatment in patients with type 2 diabetes mellitus(T2DM)". She discussed the additive efficacy in glycemic control and the tolerability of SGLT2i in T2DM patients when combined with other antihyperglycemic agents, such as metformin, sulfonylureas, and dipeptidyl peptidase-4 inhibitors using real-world data. Yoona Choi, TaeKyu Chung, and Yoomin Jeon also contributed to this study as co-researchers, with Professor Howard Lee serving as the principle investigator.

The conference was a three-day event (from Nov 23rd, 2022 to Nov 25th, 2022) and was held at The International Convention Center, Jeonbuk National University, Jeonju, Jeonbuk, South Korea. This conference, the host(KOSMI) organized the event around the theme, "The Power and Value of Healthcare Data Linkage". The conference was full of enlightening speeches that reflected the progress made in the field of medical informatics. With a total of 1,039 participants, this conference was held on the largest scale ever among KOSMI conferences.